DNA - NYSE
Ginkgo Bioworks Holdings, Inc.
$8.73
-6.4%Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotGinkgo Bioworks Holdings, Inc. Management Team
Mr. Steven P. Coen CPA
Chief Accounting Officer
Mr. Mark E. Dmytruk
Chief Financial Officer
Compensation
$460,000
Mr. Thomas Knight Jr.
Founder
Dr. Jason Kelly Ph.D.
Founder, Chief Executive Officer & Director
Compensation
$250,000
Mr. Bartholomew Canton Ph.D.
Founder, Chief Technology Officer & Secretary
Mr. Austin Che Ph.D.
Founder, Head of Strategy & Treasurer
Dr. Reshma P. Shetty
Founder, President, Chief Operating Officer & Director
Compensation
$250,000
Ms. Karen Tepichin
General Counsel & Secretary
Ms. Samantha Sutton
Head of People
Mr. Daniel Marshall
Senior Manager of Communications & Ownership
Ginkgo Bioworks Holdings, Inc. Insider Positioning
During the last 12 months, insiders have sold $3.90M worth of DNA shares, with no buying activity reported.
3 Months
0
0.00
543.3K
3.55M
-3.6M
-$3.55M
3-6 Months
0
0.00
1.7K
15.21K
-15K
-$15K
6-9 Months
0
0.00
26.9K
321.84K
-322K
-$322K
9-12 Months
0
0.00
1.4K
14.51K
-15K
-$15K
Top Buyers
No buying activity
Top Sellers
Kelly Jason R
Director, Officer: See Remarks
$1.37M
Canton Barry
10 Percent Owner
$978K
Shetty Reshma P.
Director, 10 Percent Owner, Officer: See Remarks
$978K
Coen Steven P.
Officer: See Remarks
$354K
Henry Christian O
Director
$220K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $3.90M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
DNA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 05, 2024 | August 14, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 26, 2022 | June 10, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.